Details of the Drug Combinations

General Information of This Drug (ID: DM5ZR4Q)

Drug Name

PSI-938 DM5ZR4Q

Synonyms

PSI-352938; PSI-938; UNII-3Z30JH9QX1; 3Z30JH9QX1; PSI938; PSI 938; 1231747-17-3; 1199809-32-9; SCHEMBL2679397; CHEMBL2160007; CS-6672; HY-15231; Guanosine, 2'-deoxy-6-O-ethyl-2'-fluoro-2'-methyl-, cyclic 3',5'-(1-methylethyl (R)-phosphate), (2'R)-; 9-[(4aR,6R,7R,7aR)-7-Fluoro-2-isopropoxy-7-methyl-2-oxo-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxy-purin-2-amine

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PSI-938 + Sofosbuvir	DCLV6PN	Sofosbuvir	Hepatitis C, Chronic	[2]
------------------------------------------------------------------------------------

References

1	2011 Pipeline of Pharmasset.
2	ClinicalTrials.gov (NCT01435044) Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection